Label Changes for:

Bepreve (bepotastine besilate) 1.5% ophthalmic solution

June 2012

Changes have been made to the CONTRAINDICATIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2012

 

 

CONTRAINDICATIONS
Hide
(web4)